PEC-QT / CRISPR Therap, Vertex - LARVOL DELTA

Stem Cell Therapy as a Regenerative Strategy in Hereditary Pancreatitis Postpancreatectomy. (PubMed, Ann Afr Med) - "These studies led to the creation of CRISPR VCTX210, VC-02 implants by ViaCyte. VX-880 by Vertex, in its phase 3 trial, used fully differentiated, allogenic pluripotent-stem-cell-derived islet therapy as a functional cure for type 1 diabetes...The enduring risk of insulin-dependent diabetes associated with HP can be mitigated through the regeneration of function with PSC-derived implants and MSC co-transplantation after pancreatectomy. Researchers may find this review useful in developing procedures for patient selection and monitoring, and clinicians may find it helpful in incorporating new treatments into patient care for HP."

Journal • Diabetes • Metabolic Disorders • Pancreatitis • Transplantation • Type 1 Diabetes Mellitus

GENE THERAPY AS FUNCTIONAL CURE FOR DIABETES: ARE WE THERE YET? (ICE-EDEC 2024) - "4- Genetics in gestational diabetes I will review briefly the most important genes involved in the incidence of gestational diabetes. Gene therapy and gene-edited therapy in Diabetes In my research, I will focus on the current status and the future perspectives of gene therapy and gene-edited therapy and review the updated literature addressing these two novel therapies in the management of diabetes, such as Wisconsin University clinical trial of 2013, VCTX210 trial in Canada, and other studies. Studying the role of genes in the incidence of all types of diabetes can help us in understanding the mechanism of the novel experimental therapies of T1D, principally gene therapy and gene-edited therapy... Studying the role of genes in the incidence of all types of diabetes can help us in understanding the mechanism of the novel experimental therapies of T1D, principally gene therapy and gene-edited therapy. Currently, there are several gene level interventions that are being..."

Gene therapy • Diabetes • Gene Therapies • Genetic Disorders • Gestational Diabetes • Metabolic Disorders • Obesity • Type 1 Diabetes Mellitus

An Open-Label, FIH Study Evaluating the Safety and Tolerability of VCTX210A Combination Product in Subjects With T1D (clinicaltrials.gov) - P1 | N=7 | Completed | Sponsor: CRISPR Therapeutics AG | Active, not recruiting ➔ Completed | N=10 ➔ 7

Enrollment change • Trial completion • Diabetes • Endocrine Disorders • Immunology • Metabolic Disorders • Type 1 Diabetes Mellitus

An Open-Label, FIH Study Evaluating the Safety and Tolerability of VCTX210A Combination Product in Subjects With T1D (clinicaltrials.gov) - P1 | N=10 | Active, not recruiting | Sponsor: CRISPR Therapeutics AG | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2022 ➔ Apr 2023 | Trial primary completion date: Dec 2022 ➔ Apr 2023

Enrollment closed • Trial completion date • Trial primary completion date • Diabetes • Endocrine Disorders • Immunology • Metabolic Disorders • Type 1 Diabetes Mellitus